Home > Neurology > EAN 2020 > Headache and Pain > Eptinezumab in chronic migraine and medication-overuse headache

Eptinezumab in chronic migraine and medication-overuse headache

Presented by
Prof. Hans-Christoph Diener, Medical Faculty of the University Duisburg-Essen, Germany
Conference
EAN 2020
Trial
Phase 3, PROMISE-2

In the pivotal PROMISE-2 study, eptinezumab was efficacious in patients with chronic migraine and medication-overuse headache (MOH). After 12 weeks, the eptinezumab group had a greater reduction in migraine days than the placebo group. Efficacy was noted from day 1 and sustained through 24 weeks [1].

In PROMISE-2, 1,072 chronic migraine patients participated, 431 of whom had a dual diagnosis of chronic migraine and MOH. Participants were randomised to eptinezumab 100 mg, 300 mg, or placebo for 2 intravenous doses administered every 12 weeks. Eptinezumab is an anti-calcitonin gene-related peptide monoclonal antibody. MOH patients were equally distributed in these 3 groups. During the 28-day baseline period, MOH patients experienced a mean 16.7 migraine days.

Efficacy of eptinezumab versus placebo on day 1 through 7 was lower with eptinezumab than placebo. On baseline, about 60% of participants experienced migraine; on day 1, this rate was 27.8% (100 mg); 30.1% (300 mg); and 45.5% (placebo). In all of the first 12 weeks of intervention, eptinezumab-treated patients experienced greater reductions in monthly migraine days (MMDs) than placebo patients (100 mg, -8.2; 300 mg, -8.5; placebo, -5.2). About twice as many patients in the eptinezumab groups were ‚Č•50% (60.4%; 61.9%; 34.5%) or ‚Č•75% migraine responders (27.3%; 29.9%; 14.5%). Results were similar during weeks 13-24.

  1. Diener H-C, et al. Abstract EPR1090, EAN 2020.

 



Posted on